CorMedix to acquire Heron Therapeutics assets, reports Q3 2026 resultsNov 12Quarterly updateCorMedix Inc.
CorMedix to acquire nearly all of Heron Therapeutics' assets in cash-and-stock dealNov 9M&ACorMedix Inc.Heron Therapeutics, Inc. /De/Updated
Bicara reaches substantial enrollment in HPV-negative head and neck cancer trialNov 9Quarterly updateArriVent BioPharma, Inc.Bicara Therapeutics
Heron withdraws 2026 guidance, weighs strategic alternatives after CINVANTI rulingAug 10Quarterly updateaprepitantHeron Therapeutics, Inc. /De/